Abstract 607P
Background
Melanoma brain metastasis has very poor prognosis, although recent treatment advances, including immune checkpoint inhibitors and targeted therapy, have improved the prognosis. We investigated the survival of Asian patients with melanoma brain metastasis and the effectiveness of radiotherapy and systemic therapies.
Methods
We retrospectively reviewed the survival rates of patients diagnosed with melanoma brain metastasis between January 2011 and December 2021 at the National Cancer Center Hospital in Tokyo, Japan. In addition, we identified factors associated with survival using Cox regression analysis.
Results
A total of 135 patients were included. The median overall survival after melanoma brain metastasis diagnosis was 7.8 months (95% confidence interval [CI] 6.1–9.6). The 6-month and 1-year survival rates were 60.7% and 34.8%, respectively. We identified the prognostic factors of melanoma brain metastasis, including non-acral primary location, low serum LDH levels, systemic therapy of single-agent immune check point inhibitors or targeted therapies, and radiotherapy of stereotactic irradiation. On the other hand, We found no significant difference in effectiveness between single-agent immune check point inhibitors, the combination of immune check point inhibitors, and targeted therapies.
Conclusions
We retrospectively investigated the survival of patients with melanoma brain metastasis at our facility. The survival of Asian patients with melanoma brain metastasis is relatively poor compared to that of Caucasian patients. Immune check point inhibitor, targeted therapy, and radiotherapy of stereotactic irradiation were associated with improved survival; however, we found no significant superiority of the combination of immune check point inhibitors over single-agent immune check point inhibitor or targeted therapy in terms of effectiveness. Further investigations using larger cohorts, multicenter analyses, and prospective studies are necessary to assess the effectiveness of systemic therapy in Asian patients with melanoma brain metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dermatologic oncology department in National Cancer Center Hospital.
Funding
Has not received any funding.
Disclosure
N. Yamazaki: Financial Interests, Personal, Advisory Board: Ono, Chugai; Financial Interests, Personal, Invited Speaker: Ono, Bristol Myers Squibb, Novartis, MSD, Maruho; Financial Interests, Institutional, Research Grant: Ono, Bristol Myers Squibb, Novartis, Amgen. K. Namikawa: Financial Interests, Personal, Advisory Board: MSD, Novartis; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb, Novartis, MSD, Ono. All other authors have declared no conflicts of interest.
Resources from the same session
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract